Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annu...( SEATTLE WA May 30 / Oncothyreon Inc. ...)

SEATTLE, WA, May 30 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that data from clinical trials for three of the Company's product candidates were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 30, 2009 in Orlando, Florida. The presentations included long-term safety data from the Phase 2b trial of Stimuvax(R) in patients with stage IIIB/IV non-small cell lung cancer, preliminary results from the Phase 1 trial of the phosphoinositide-3-kinase (PI-3 kinase) inhibitor PX-866 in patients with advanced malignancy, and final results from two Phase 1b trials of the thioredoxin inhibitor PX-12 in advanced cancer patients.

Stimuvax

Data concerning the long-term safety of Stimuvax (BLP25 liposomal vaccine) were presented by Dr. Charles Butts, Cross Cancer Institute, Edmonton, Alberta. Sixteen patients who received Stimuvax for between 2 and 8.2 years as part of the Phase 2b trial in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) were studied. Ten of these patients have been treated for more than five years, and eight continue to receive therapy with Stimuvax. Prolonged treatment with Stimuvax was well-tolerated in this trial. The most common treatment-related adverse events were injection site reactions, which tended to diminish after the first year of treatment. There was no evidence of autoimmune reactions with prolonged use.

"We are very pleased that this group of long-term survivors with advanced NSCLC has been able to continue to receive Stimuvax with apparent safety for up to eight years," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Oncothyreon. "These patients were treated as part of the randomized Phase 2b trial conducted by Oncothyreon, in which the subset of patients with Stage IIIb locoregi
'/>"/>